Robust intrapulmonary CD8 T cell responses and protection with an attenuated N1L deleted vaccinia virus

PLoS ONE

Volumn 3, Issue 10, 2008, Pages

  Mathew, Anuja ^a   O'Bryan, Joel ^a   Marshall, William ^a   Kotwal, Girish J ^a   Terajima, Masanori ^a   Green, Sharone ^a   Rothman, Alan L ^a   Ennis, Francis A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINIA ANTIBODY; VACCINIA VACCINE; N1L PROTEIN, VACCINIA VIRUS; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENE INACTIVATION; IMMUNOGENICITY; LUNG INFECTION; MOUSE; NONHUMAN; STRAIN DIFFERENCE; VACCINIA; VACCINIA VIRUS; VIRUS STRAIN; VIRUS VIRULENCE; WILD TYPE; ANIMAL; B LYMPHOCYTE; C57BL MOUSE; GENETICS; IMMUNOLOGY;

MUS; VACCINIA VIRUS;

ANIMALS; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; MICE; MICE, INBRED C57BL; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 54149118187     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003323     Document Type: Article

References (38)

1. Rosenthal SR, Merchlinsky M, Kleppinger C, Goldenthal KL (2001) Developing new small pox vaccines. Emerg Infect Dis 7: 920-926.
2. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA (2003) Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis 37: 251-271.
3. Turner GS (1967) Respiratory infection of mice with vaccinia virus. J Gen Virol 1: 399-402.
4. Harrington LE, Most Rv R, Whitton JL, Ahmed R (2002) Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol 76: 3329-3337.
5. Smee DF, Bailey KW, Sidwell RW (2001) Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antivir Chem Chemother 12: 71-76.
6. Williamson JD, Reith RW, Jeffrey LJ, Arrand JR, Mackett M (1990) Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J Gen Virol 71 (Pt 11): 2761-2767.
7. Andrew ME, Coupar BE, Boyle DB (1989) Humoral and cell-mediated immune responses to recombinant vaccinia viruses in mice. Immunol Cell Biol 67 (Pt 5): 331-337.
8. Haga IR, Bowie AG (2005) Evasion of innate immunity by vaccinia virus. Parasitology 130 Suppl: S11-25.
9. Gurt I, Abdalrhman I, Katz E (2006) Pathogenicity and immunogenicity in mice of vaccinia viruses mutated in the viral envelope proteins A33R and B5R. Antiviral Res 69: 158-164.
10. Reading PC, Smith GL (2003) Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity. J Virol 77: 9960-9968.
11. Reading PC, Moore JB, Smith GL (2003) Steroid hormone synthesis by vaccinia virus suppresses the inflammatory response to infection. J Exp Med 197: 1269-1278.
12. Clark RH, Kenyon JC, Bartlett NW, Tscharke DC, Smith GL (2006) Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol 87: 29-38.
13. Bartlett N, Symons JA, Tscharke DC, Smith GL (2002) The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. J Gen Virol 83: 1965-1976.
14. Kotwal GJ, Hugin AW, Moss B (1989) Mapping and insertional mutagenesis of a vaccinia virus gene encoding a 13,800-Da secreted protein. Virology 171: 579-587.
15. DiPerna G, Stack J, Bowie AG, Boy dA, Kotwal G, et al. (2004) Pox virus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem 279: 36570-36578.
16. Zhang Z, Abrahams MR, Hunt LA, Suttles J, Marshall W, et al. (2005) The Vaccinia Virus N1L Protein Influences Cytokine Secretion in Vitro after Infection. Ann N Y Acad Sci 1056: 69-86.
17. Aoyagi M, Zhai D, Jin C, Aleshin AE, Stec B, et al. (2007) Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. Protein Sci 16: 118-124.
18. Cooray S, Bahar MW, Abrescia NG, McVey CE, Bartlett NW, et al. (2007) Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J Gen Virol 88: 1656-1666.
19. Billing B, Smith SA, Zhang Z, Lahiri DK, Kotwal GJ (2004) Lack of N1L gene expression results in a significant decrease of vaccinia virus replication in mouse brain. Ann N Y Acad Sci 1030: 297-302.
20. Tscharke DC, Karupiah G, Zhou J, Palmore T, Irvine KR, et al. (2005) Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 201: 95-104.
21. Smee DF, Bailey KW, Wong MH, Sidwell RW (2001) Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res 52: 55-62.
22. Phelps A, Gates AJ, Hillier M, Eastaugh L, Ulaeto DO (2005) Comparative efficacy of replicating smallpox vaccine strains in a murine challenge model. Vaccine 23: 3500-3507.
23. Hayasaka D, Ennis FA, Terajima M (2007) Pathogeneses of respiratory infections with virulent and attenuated vaccinia viruses. Virol J 4: 22.
24. Reed LaM H (1938) A simple method of estimating 50% end points. American Journal of Hygiene 27: 493-497.
25. Karin M, Lin A (2002) NF-kappaB at the crossroads of life and death. Nat Immunol 3: 221-227.
26. Graham SC, Bahar MW, Cooray S, Chen RA, Whalen DM, et al. (2008) Vaccinia virus proteins A52 and B14 Share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis. PLoS Pathog 4: e1000128.
27. Adams JM, Cory S (1998) The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326.
28. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, et al. (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608.
29. de Moissac D, Zheng H, Kirshenbaum LA (1999) Linkage of the BH4 domain of Bcl-2 and the nuclear factor kappaB signaling pathway for suppression of apoptosis. J Biol Chem 274: 29505-29509.
30. Hiscott J (2007) Convergence of the NF-kappaB and IRF pathways in the regulation of the innate antiviral response. Cytokine Growth Factor Rev 18: 483-490.
31. Parker LC, Whyte MK, Dower SK, Sabroe I (2005) The expression and roles of Toll-like receptors in the biology of the human neutrophil. J Leukoc Biol 77: 886-892.
32. Reed JC, Tsujimoto Y, Alpers JD, Croce CM, Nowell PC (1987) Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. Science 236: 1295-1299.
33. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA (1999) Phylogenetic perspectives in innate immunity. Science 284: 1313-1318.
34. Medzhitov R, Janeway CA Jr (1998) Innate immune recognition and control of adaptive immune responses. Semin Immunol 10: 351-353.
35. Woodland DL, Hogan RJ, Zhong W (2001) Cellular immunity and memory to respiratory virus infections. Immunol Res 24: 53-67.
36. Wiley JA, Hogan RJ, Woodland DL, Harmsen AG (2001) Antigen-specific CD8(+) T cells persist in the upper respiratory tract following in fluenza virus infection. J Immunol 167: 3293-3299.
37. Lawrence CW, Ream RM, Braciale TJ (2005) Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection. J Immunol 174: 5332-5340.
38. Mathew A, Terajima M, West K, Green S, Rothman AL, et al. (2005) Identification of murine poxvirus-specific CD8+ CTL epitopes with distinct functional profiles. J Immunol 174: 2212-2219.